Literature DB >> 15924878

2',5'-Oligoadenylate size is critical to protect RNase L against proteolytic cleavage in chronic fatigue syndrome.

Marc Frémont1, Karim El Bakkouri, Freya Vaeyens, C Vincent Herst, Kenny De Meirleir, Patrick Englebienne.   

Abstract

A dysregulation in the 2',5'-oligoadenylate (2-5A)-dependent RNase L antiviral pathway has been detected in peripheral blood mononuclear cells (PBMC) of chronic fatigue syndrome (CFS) patients, which is characterized by upregulated 2-5A synthetase and RNase L activities, as well as by the presence of a low molecular weight (LMW) 2-5A-binding protein of 37-kDa related to RNase L. This truncated protein has been shown to originate from proteolytic cleavage of the native 83-kDa RNase L by m-calpain and human leukocyte elastase (HLE). We investigated the possible role of 2-5A oligomers in the proteolytic action toward the endonuclease and show that incubation of CFS PBMC extracts with 2-5A trimer and tetramer, but not with the dimer, results in a significant protection of the native 83-kDa RNase L against cleavage by endogenous and purified proteases. Similar results are obtained with a purified recombinant RNase L. An analysis of the size of 2-5A oligomers produced by the catalytic activity of the 2-5A synthetase present in PBMC extracts further shows that samples containing the 37-kDa RNase L preferentially produce 2-5A dimers instead of higher oligomers. Taken together, our results indicate that homodimerization of RNase L by 2-5A oligomers higher than the dimer prevents its cleavage by proteolytic enzymes. The presence of the truncated 37-kDa RNase L in PBMC extracts is therefore likely to result, not only from the abnormal activation of inflammatory proteases, but also from a dysregulation in 2-5A synthetase induction or activation towards the preferential production of 2-5A dimers.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15924878     DOI: 10.1016/j.yexmp.2005.01.003

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  6 in total

Review 1.  Diverse functions of RNase L and implications in pathology.

Authors:  Catherine Bisbal; Robert H Silverman
Journal:  Biochimie       Date:  2007-02-20       Impact factor: 4.079

2.  Infection, viral dissemination, and antibody responses of rhesus macaques exposed to the human gammaretrovirus XMRV.

Authors:  Nattawat Onlamoon; Jaydip Das Gupta; Prachi Sharma; Kenneth Rogers; Suganthi Suppiah; Jeanne Rhea; Ross J Molinaro; Christina Gaughan; Beihua Dong; Eric A Klein; Xiaoxing Qiu; Sushil Devare; Gerald Schochetman; John Hackett; Robert H Silverman; François Villinger
Journal:  J Virol       Date:  2011-02-16       Impact factor: 5.103

3.  Expression, purification and characterization of the interferon-inducible, antiviral and tumour-suppressor protein, human RNase L.

Authors:  Ankush Gupta; Pramod C Rath
Journal:  J Biosci       Date:  2012-03       Impact factor: 1.826

Review 4.  Pathologic effects of RNase-L dysregulation in immunity and proliferative control.

Authors:  Heather J Ezelle; Bret A Hassel
Journal:  Front Biosci (Schol Ed)       Date:  2012-01-01

5.  Curcumin, a natural antioxidant, acts as a noncompetitive inhibitor of human RNase L in presence of its cofactor 2-5A in vitro.

Authors:  Ankush Gupta; Pramod C Rath
Journal:  Biomed Res Int       Date:  2014-09-02       Impact factor: 3.411

Review 6.  Efficacy of rintatolimod in the treatment of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME).

Authors:  William M Mitchell
Journal:  Expert Rev Clin Pharmacol       Date:  2016-06       Impact factor: 5.045

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.